Evidence map›Paper›PMID 39901938›Full record

ArticleCurrent therapeutic research, clinical and experimental2025

Effect of Hematopoietic Stem Cell Transplantation Regimen on Tacrolimus Pharmacokinetics.

Haruno Oku, Saki Yoshida, Takumi Hotta, Hirohito Muroi, Keizo Fukushima, Kei Irie, Tatsuya Hirano, Yoshimitsu Shimomura, Takayuki Ishikawa, Hiroaki Ikesue and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current therapeutic research, clinical and experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Haruno OkuDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.
Saki YoshidaDepartment of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Takumi HottaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.
Hirohito MuroiDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.
Keizo FukushimaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.
Kei IrieDepartment of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Tatsuya HiranoDepartment of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Hiroaki IkesueDepartment of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Nobuyuki MuroiDepartment of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Tohru HashidaDepartment of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan.
Nobuyuki SugiokaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Treatment with tacrolimus requires strict control of the whole-blood concentration in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). In patients undergoing cord blood transplantation (CBT), there is a negative correlation between volume of distribution of tacrolimus and hemoglobin levels, which reflect the red blood cell (RBC) count. In this study, we evaluated the influence of the conditioning regimen (myeloablative and reduced-intensity conditioning) or donor source (cord blood, bone marrow, and peripheral blood stem cells) on the pharmacokinetics of tacrolimus in patients undergoing HSCT, including those undergoing CBT. We also examined applicability of dosing strategy of tacrolimus considering the RBC count. Methods: We retrospectively analyzed clinical data-including whole-blood tacrolimus concentrations-from patients with HSCT. The observation period spanned from first continuous intravenous infusions until switch to oral medication, transfer to another hospital, relapse, or death. Population pharmacokinetic analysis was performed on whole-blood tacrolimus concentrations obtained from therapeutic drug monitoring during the observation period. Patient characteristics and laboratory data were evaluated as covariates. Results: We enrolled 91 patients undergoing HSCT (CBT: Conclusions: A tacrolimus dosing strategy that considers the variability in hemoglobin levels applies to all patients undergoing HSCT.

Indexed as

hematopoietic stem cell transplantationpopulation pharmacokineticstacrolimustherapeutic drug monitoring

Identifiers

PMID39901938
PMCPMC11788801

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.